Edition:
United States

Abbott Laboratories (ABT.N)

ABT.N on New York Stock Exchange

59.71USD
23 Feb 2018
Change (% chg)

$0.72 (+1.22%)
Prev Close
$58.99
Open
$59.24
Day's High
$59.74
Day's Low
$58.98
Volume
1,307,529
Avg. Vol
1,775,231
52-wk High
$64.60
52-wk Low
$42.32

Chart for

About

Abbott Laboratories is engaged in the discovery, development, manufacture and sale of a range of healthcare products. The Company operates through four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products and Vascular Products. Its Established Pharmaceutical Products include a range of branded... (more)

Overall

Beta: 1.55
Market Cap(Mil.): $103,931.30
Shares Outstanding(Mil.): 1,740.60
Dividend: 0.28
Yield (%): 1.88

Financials

  Industry Sector
P/E (TTM): -- 30.96 16.59
EPS (TTM): -- -- --
ROI: -- 14.08 35.07
ROE: -- 15.71 17.79

BRIEF-Abbott Sets Quarterly Dividend Of $0.28/Share

* ABBOTT SETS QUARTERLY DIVIDEND OF $0.28PER SHARE Source text for Eikon: Further company coverage:

Feb 16 2018

Exclusive: J&J out of race for Pfizer's $20 billion consumer unit as deadline looms

LONDON/NEW YORK/FRANKFURT Johnson & Johnson has pulled out of the race to buy Pfizer's consumer health business, leaving GlaxoSmithKline and Reckitt Benckiser among those preparing bids, according to sources familiar with the matter.

Jan 25 2018

Deals of the day-Mergers and acquisitions

Jan 24 The following bids, mergers, acquisitions and disposals were reported by 2030 GMT on Wednesday:

Jan 24 2018

Abbott to take a pause after deal spree

Abbott Laboratories said on Wednesday it was not looking at acquisitions this year as the healthcare company looks to ease its debt burden after a spree of deals last year.

Jan 24 2018

UPDATE 3-Abbott to take a pause after deal spree

* Successful integration of recent deals an "execution story"- analyst

Jan 24 2018

BRIEF-Abbott Posts Q4 Adj. EPS $0.74 From Continuing Operations

* SEES Q1 2018 ADJUSTED EARNINGS PER SHARE $0.57 TO $0.59 FROM CONTINUING OPERATIONS EXCLUDING ITEMS

Jan 24 2018

Abbott posts quarterly loss on $1.4 bln tax charge

Jan 24 Abbott Laboratories reported fourth-quarter loss on Wednesday compared with a year-ago profit, as the diversified healthcare company took a $1.4 billion charge due to the recent U.S. tax overhaul. It posted a net loss of $828 million, or 48 cents per share, in the quarter ended Dec. 31 compared with a profit of $798 million, or 53 cents per share, a year earlier.

Jan 24 2018

Abbott Laboratories expected to post earnings of 73 cents  a share - summary

* Abbott Laboratories is expected to show a rise in quarterly revenue when it reports results on January 24.

Jan 22 2018

BRIEF-Biogaia signs deal with Abbott to launch probiotic in China

* SAYS HAS SIGNED AN EXCLUSIVE AGREEMENT WITH ABBOTT FOR RIGHTS TO COMMERCIALIZE BIOGAIA PROTECTIS TABS IN CHINA

Jan 18 2018

CMS to cover Abbott's glucose monitoring device

Abbott Laboratories said on Thursday its newly launched glucose monitoring device would be covered by the Centers for Medicare & Medicaid Services, expanding its usage to millions of diabetes patients in the United States.

Jan 04 2018

Competitors

  Price Chg
Johnson & Johnson (JNJ.N) $132.02 +2.11
Pfizer Inc. (PFE.N) $36.26 +0.52
Novartis AG (NOVN.S) CHF79.38 -0.60
Merck & Co., Inc. (MRK.N) $54.87 +0.30
Sanofi SA (SASY.PA) €65.05 +0.16
AstraZeneca plc (AZN.L) 4,752.00 -20.00
GlaxoSmithKline plc (GSK.L) 1,296.00 -7.00
Eli Lilly and Co (LLY.N) $78.75 +1.56
Amgen, Inc. (AMGN.OQ) $186.67 +4.22
Boston Scientific Corporation (BSX.N) $27.20 +0.72

Earnings vs. Estimates